Is Sarolaner safe for dogs and cats?
Low risk for petsFDA-approved. Rare neurologic events in susceptible dogs.
What is sarolaner?
- CAS number
- 1398609-91-2
- Molecular formula
- C24H22Cl2F5N3O5S2
- Molecular weight
- 648.48 g/mol
- SMILES
- CC1(CC1C(=O)NC2=CC(=CC(=C2Cl)OC(F)F)S(=O)(=O)C3=CC(=NN3)C(F)(F)F)CS(=O)(=O)C
- PubChem CID
- 71455818
Risk for dogs
Low riskFDA-approved. Rare neurologic events in susceptible dogs.
Risk for cats
Low riskPart of Revolution Plus — approved for cats.
Regulatory consensus
1 regulatory bodyhas classified Sarolaner.
| Agency | Year | Classification | Notes |
|---|---|---|---|
| FDA | 2016 | Approved veterinary drug (NADA 141-468) |
Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.
Where pets encounter sarolaner
- Veterinary Medicine
Safer alternatives
Lower-risk approaches that achieve a similar outcome to Sarolaner:
-
Fluralaner (Bravecto)
Trade-offs: Alternative approach; specific tradeoffs depend on application context, scale, and regulatory requirements. Full hazard assessment of alternative recommended before adoption to avoid regrettable substitution.Relative cost: 1.2-2×
-
Afoxolaner (NexGard)
Trade-offs: Alternative approach; specific tradeoffs depend on application context, scale, and regulatory requirements. Full hazard assessment of alternative recommended before adoption to avoid regrettable substitution.Relative cost: 1.2-2×
Frequently asked questions
Is sarolaner safe for pets?
FDA-approved. Rare neurologic events in susceptible dogs.
See Sarolaner in the pets app
Look up products containing sarolaner, compare to alternatives, and explore the full data record.
Open in pets View raw API dataSources (1)
- —
Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →